Volume 5.44 | Nov 21

Prostate Cell News 5.44 November 21, 2014
Prostate Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PCN on Twitter
The ​Estrogen Receptor Alpha-Regulated lncRNA ​NEAT1 Is a Critical Modulator of Prostate Cancer
Among putatively estrogen receptor alpha-regulated intergenic long non-coding RNAs (lncRNAs), scientists identified ​nuclear enriched abundant transcript 1 (​NEAT1) as the most significantly overexpressed lncRNA in prostate cancer. Prostate cancer cells expressing high levels of NEAT1 were recalcitrant to androgen or androgen receptor antagonists. [Nat Commun] Full Article
New TeSR™-E8™ is Here For Feeder-Free Culture of Human ES Cells and iPS Cells
PUBLICATIONS (Ranked by impact factor of the journal)

AGE Modified Basement Membrane Cooperates with Endo180 to Promote Epithelial Cell Invasiveness and Decrease Prostate Cancer Survival
Scientists hypothesized that the structural alterations in the basal lamina associated with age can induce mechanotransduction pathways in prostate epithelial cells to promote invasiveness and cancer progression.
[J Pathol]

MicroRNA-940 Suppresses Prostate Cancer Migration and Invasion by Regulating MIEN1
A novel microRNA (miRNA), hsa-miR-940 (miR-940), identified and validated to be highly expressed in immortalized normal cells compared to cancer cells, is a regulator of migration and invasion enhancer 1 (MIEN1). Analysis of human prostate tumors and their matched normal tissues confirmed that miR-940 is highly expressed in the normal tissues compared to its low to negligible expression in the tumors. [Mol Cancer] Abstract | Full Article

Combination Simvastatin and Metformin Induces G1-Phase Cell Cycle Arrest and Ripk1- and Ripk3-Dependent Necrosis in C4-2B Osseous Metastatic Castration-Resistant Prostate Cancer Cells
Treatment of C4-2B cells with combination 4μM simvastatin and 2mM metformin led to significant G1-phase cell cycle arrest and decrease in the percentage of DNA-replicating cells in the S-phase by 24 hours; arrest was sustained throughout the 96-hour treatment. [Cell Death Dis] Full Article

Apigenin Manipulates the Ubiquitin-Proteasome System to Rescue Estrogen Receptor-β from Degradation and Induce Apoptosis in Prostate Cancer Cells
Researchers investigated apigenin, a dietary flavonoid with proteasome-inhibitory activity, against FDA-approved anticancer proteasome inhibitor bortezomib in context to its effects on the tumor suppressor estrogen receptor-beta in prostate cancer cells. [Eur J Nutr] Abstract

The Cytotoxic and Pro-Apoptotic Activities of the Novel Fluoropyrimidine F10 towards Prostate Cancer Cells Are Enhanced by Zn2+-Chelation and Inhibiting the Serine Protease Omi/HtrA2
To test the hypothesis that the pro-apoptotic effects of F10 could be enhanced by modulating intracellular Zn2+ scientists investigated cell-permeable and cell-impermeable Zn2+ chelators and exogenous Zn2+ and evaluated cell viability and apoptosis in cellular models of castration-resistant prostate cancer. [Prostate] Abstract

Differential Effects of Tissue Culture Coating Substrates on Prostate Cancer Cell Adherence, Morphology and Behavior
To improve the adherence of LNCaP cells to the culture surface, researchers compared different coating reagents and culturing conditions and analyzed their impact on cell proliferation, adhesion, morphology, mobility and gene expression using real-time technologies. [PLoS One] Full Article

Comprehensive Study of Gene and MicroRNA Expression Related to Epithelial-Mesenchymal Transition in Prostate Cancer
Scientists analyzed gene and microRNA expression involved in epithelial-mesenchymal transition in localized prostate cancer and metastatic prostate cancer cell lines and correlate with clinicopathological findings. They studied 51 fresh frozen tissue samples from patients with localized prostate cancer treated by radical prostatectomy and three metastatic prostate cancer cell lines. [PLoS One] Full Article

NSK-01105 Inhibits Proliferation and Induces Apoptosis of Prostate Cancer Cells by Blocking the Raf/MEK/ERK and PI3K/Akt/mTOR Signal Pathways
Researchers investigated the antitumor activities of NSK-01105, a novel sorafenib derivative, in in vitro and in vivo models, and explored the potential mechanisms. [Tumor Biol] Abstract

Antiproliferative Activity of Aqueous Leaf Extract of Annona muricata L. on the Prostate, BPH-1 Cells, and Some Target Genes
Annona muricata L. has been reported to possess antitumor and antiproliferative properties. Scientists determined the effect of A. muricata on human BPH-1 cells and prostate organ. [Integr Cancer Ther] Abstract


A Phase I Study of TRC105 Anti-CD105 (Endoglin) Antibody in Metastatic Castration-Resistant Prostate Cancer
Scientists evaluated the safety, pharmacokinetics, and pharmacodynamics of TRC105 in patients with metastatic castration-resistant prostate cancer. [BJU Int] Abstract

Evaluation of PSF1 as a Prognostic Biomarker for Prostate Cancer
Scientists evaluated the relationship between partner of SLD5 1 (PSF1) expression and the clinical features of prostate cancer. They show that the PSF1 expression correlated significantly with PSA values at diagnosis, with tumor grade, and with clinical stage. [Prostate Cancer Prostatic Dis] Abstract

Listen Now: Podcast on ALDH in Breast Cancer Treatment Response
The Epigenetics of Prostate Cancer Diagnosis and Prognosis: Update on Clinical Applications
Epigenetic changes are associated with prostate cancer development and progression. The authors focus on recent results in the clinical application of diagnostic and prognostic epigenetic markers. [Curr Opin Urol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
Galeterone Shows Activity in a Variant Form of Castration-Resistant Prostate Cancer
Results from a trial of the anti-cancer drug galeterone show that it is successful in lowering prostate-specific antigen levels in men with a form of prostate cancer that is resistant to treatment with hormone therapy. [Press release from European CanCer Organisation (ECCO) discussing research presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona] Press Release

From our sponsor: Learn about assays for cord blood. Download the free technical bulletin.
Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio’s Hepatitis B Immunotherapy
Inovio Pharmaceuticals, Inc. announced the company and Roche have terminated their 2013 collaboration, option, and license agreement to co-develop INO-5150, Inovio’s DNA immunotherapy targeting prostate cancer, as well as their research collaboration in prostate cancer. [Inovio Pharmaceuticals, Inc.] Press Release

SOTIO Initiates US Part of VIABLE, a Global Phase III Clinical Trial for Prostate Cancer Immunotherapy Treatment Using DCVAC/PCa
SOTIO announced that the first US patient has been enrolled in its VIABLE study, the global Phase III clinical trial for DCVAC/PCa, an active cellular immunotherapy treatment for prostate cancer patients. [SOTIO, LLC] Press Release

Tokai Pharmaceuticals Presents Updated Interim Galeterone ARMOR2 Data Showing Activity in Patients with Castration-Resistant Prostate Cancer (CRPC) including Those Showing a Variant Form of Prostate Cancer Resistant to Hormone Therapy
Tokai Pharmaceuticals, Inc. announced updated interim results from its ongoing ARMOR2 Phase II clinical trial of galeterone in CRPC patients. [Tokai Pharmaceuticals, Inc.] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Advances in Cancer Immunotherapy 2014
December 5, 2014
Tampa, United States

Visit our events page to see a complete list of events in the prostate cell community.
NEW Postdoctoral Researcher – Chromatin and Epigenetic Regulation (Van Andel Research Institute)

NEW Associate Professor – Physiology (University of Bergen)

Postdoctoral Position – Prostate Cancer (Roswell Park Cancer Institute)

Postdoctoral Position – Prostate Cancer and Prostatic Diseases (Louisiana State University)

Postdoctoral Associate – Biomarkers Associated with Prostate Cancer (Duke Molecular Physiology Institute)

Head of Cellular and Molecular Therapies Laboratory (NHS Blood & Transplant)

Postdoctoral Fellow – Metabolomics and Prostate Cancer (University of Maryland)

Postdoctoral Fellow – Role of Deregulated PTEN/FOXO1 Pathway in Prostate Cancer (Mayo Clinic)

Postdoctoral Fellow – Oncology (Johnson & Johnson Pharmaceutical Research & Development)

Postdoctoral Fellow – Prognostic Biomarkers for Prostate Cancer (McGill University)

Physician Scientist – Prostate Cancer Genomics (University of Chicago)

Tenure Track Position – Cancer Biology (Wake Forest Baptist Medical Center)

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us